Neoplasms, Squamous Cell clinical trials

The registry lists 111 studies for Neoplasms, Squamous Cell across more than 10 countries. 19 are recruiting or about to start. 46 of them are mainly about Neoplasms, Squamous Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 7 narrower conditions too, such as Squamous Cell Carcinoma of Head and Neck: 3,303 studies, 944 open.

Get an email when these change. Save the Neoplasms, Squamous Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 46
Status unknown: 19
Terminated: 18
Recruiting: 14
Active, not recruiting: 5
Not yet recruiting: 4

Phase

Phase 2: 52
Phase 1: 32
Phase 3: 14
Early Phase 1: 4
Phase 4: 2

Where

United States: 58
China: 15
France: 12
United Kingdom: 9
Germany: 7
Canada: 7

Who runs them

Memorial Sloan Kettering Cancer Center (5) · Merck KGaA, Darmstadt, Germany (4) · Genmab (3) · Revolution Medicines, Inc. (3) · M.D. Anderson Cancer Center (3) · Hookipa Biotech GmbH (3) · Shanghai Junshi Bioscience Co., Ltd. (2) · Sesen Bio, Inc. (2)

What is being tested here

Drugs under test in Neoplasms, Squamous Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ordastobart	1	0	1
Benmelstobart	1	0	1
Cetuximab	0	0	5
Pembrolizumab	0	0	3
Zalutumumab	0	1	3
HB-201	0	1	2
HB-202	0	1	2
Docetaxel	0	0	2
Oportuzumab monatox	0	1	2
Bevacizumab	0	0	1

Drug classes tested here Immune checkpoint inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 4 · Antimitotic agents 3

Coming up

1phase 3 study under way

6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Nov 2026Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients · Jiangxi Provincial Cancer Hospital
Dec 2026Hypofractionated Radiotherapy for HNSCC in Elderly Patients · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mar 2027Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) · Falo, Louis, MD
Jul 2027Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · National Cancer Institute (NCI)
Sep 2027A Study of ZW251 in Participants With Advanced Solid Tumors · Zymeworks BC Inc.
Sep 2027Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base · Sun Yat-sen University

Who these studies take

Of the 14 Neoplasms, Squamous Cell studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.

Recruiting studies that take each age, of 14
Age	Women	Men
10	0 (0%)	0 (0%)
18	14 (100%)	14 (100%)
30	14 (100%)	14 (100%)
40	14 (100%)	14 (100%)
50	14 (100%)	14 (100%)
65	14 (100%)	14 (100%)
75	13 (93%)	13 (93%)
85	11 (79%)	11 (79%)

Across all 111 studies, recruiting or not: 15% stop at 75 or younger and 1% at 65; 5% take children; 3% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 111. Browse all 111 → or search them.